Om

Sangamo Therapeutics Inc. is a clinical-stage genomic medicine company focused on developing innovative therapies to treat serious diseases. Its primary purpose is to translate advanced genomic technologies into transformative medicines for patients with conditions such as Fabry disease, hemophilia A, and immune-mediated rejection in kidney transplantation. Key clinical-stage product candidates include ST-920, a gene therapy in Phase 1/2 for Fabry disease; TX200, a CAR-Treg therapy in Phase 1/2 for preventing rejection in HLA-A2 mismatched kidney transplants; and SB-525, a gene therapy in Phase 3 for moderately severe to severe hemophilia A. The company also advances preclinical programs targeting tauopathies, ALS/FTD, and Huntington's disease. Sangamo Therapeutics Inc. maintains strategic partnerships with leading biopharma companies like Pfizer, Novartis, and Sanofi to support its pipeline development. Operating in the genomic medicine sector, it plays a significant role in advancing gene therapy and cell therapy solutions for rare genetic disorders and neurological conditions in the United States.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I SANGAMO THERAPEUTICS MED ENDAVU: Køb Sangamo Therapeutics ($GBY) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Sangamo Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.